Literature DB >> 18981766

Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy.

Adriana Weinberg1, Ruth Dickover, Paula Britto, Chengcheng Hu, Julie Patterson-Bartlett, Joyce Kraimer, Howard Gutzman, William T Shearer, Mobeen Rathore, Ross McKinney.   

Abstract

BACKGROUND: The goal of HAART is to promote reconstitution of CD4+ T cells and other immune responses. We evaluated the extent and the kinetics of immune reconstitution in HIV-infected children over 144 weeks of successful HAART.
METHODS: Thirty-seven children receiving their first HAART regimen had plasma HIV RNA; T cells and subpopulations; T-cell rearrangement excision circles (TREC) DNA; candida, HIVCD4 and HIVCD8 enzyme-linked immunospot measured at regular intervals.
RESULTS: Plasma HIV RNA became undetectable in 81% of patients at 24 weeks and remained undetectable in 77% at 144 weeks. In contrast, CD4+% continuously increased. Distribution of T-cell subpopulations changed rapidly during the first 48 weeks of HAART and more slowly thereafter. At 144 weeks, total, naive and activated CD4+% and naive CD8+% of HIV-infected children were not significantly different from those of healthy age-matched controls, whereas total and activated CD8+% remained elevated. CD4 and CD8 TREC content increased only during the first 48 weeks of HAART. They positively correlated with each other and with total CD4+%, naive CD4+% and naive CD8+%. Candida and HIVCD4 enzyme-linked immunospot increased over time reaching peak values at 48 weeks and 144 weeks, respectively. HIVCD8 enzyme-linked immunospot decreased in magnitude over 144 weeks of HAART but retained its breadth. Baseline CD4+% positively correlated with CD4+% and with functional immune reconstitution at week 144, whereas baseline TREC correlated with TREC at week 144.
CONCLUSION: HIV-infected children acquired normal distribution of CD4 T cells and other subpopulations and recovered CD4-mediated HIV immunity after 144 weeks of HAART.

Entities:  

Mesh:

Year:  2008        PMID: 18981766      PMCID: PMC2748303          DOI: 10.1097/QAD.0b013e3283189bb3

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  48 in total

Review 1.  Cellular immune responses to HIV.

Authors:  A J McMichael; S L Rowland-Jones
Journal:  Nature       Date:  2001-04-19       Impact factor: 49.962

2.  Evaluation of T cell receptor gene rearrangement excision circles after antiretroviral therapy in children infected with human immunodeficiency virus.

Authors:  S Chavan; B Bennuri; M Kharbanda; A Chandrasekaran; S Bakshi; S Pahwa
Journal:  J Infect Dis       Date:  2001-04-13       Impact factor: 5.226

3.  Evidence for increased T cell turnover and decreased thymic output in HIV infection.

Authors:  D C Douek; M R Betts; B J Hill; S J Little; R Lempicki; J A Metcalf; J Casazza; C Yoder; J W Adelsberger; R A Stevens; M W Baseler; P Keiser; D D Richman; R T Davey; R A Koup
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

4.  Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1.

Authors:  S L Gortmaker; M Hughes; J Cervia; M Brady; G M Johnson; G R Seage; L Y Song; W M Dankner; J M Oleske
Journal:  N Engl J Med       Date:  2001-11-22       Impact factor: 91.245

5.  Long-term nonprogressive infection with human immunodeficiency virus type 1 in a hemophilia cohort.

Authors:  T C Greenough; D B Brettler; F Kirchhoff; L Alexander; R C Desrosiers; S J O'Brien; M Somasundaran; K Luzuriaga; J L Sullivan
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

6.  Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection.

Authors:  M D Hazenberg; S A Otto; J W Cohen Stuart; M C Verschuren; J C Borleffs; C A Boucher; R A Coutinho; J M Lange; T F Rinke de Wit; A Tsegaye; J J van Dongen; D Hamann; R J de Boer; F Miedema
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

7.  Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS.

Authors:  C Chougnet; S Jankelevich; K Fowke; D Liewehr; S M Steinberg; B U Mueller; P A Pizzo; R Yarchoan; G M Shearer
Journal:  J Infect Dis       Date:  2001-06-08       Impact factor: 5.226

8.  Immunologic response to combination nucleoside analogue plus protease inhibitor therapy in stable antiretroviral therapy-experienced human immunodeficiency virus-infected children.

Authors:  W Borkowsky; K Stanley; S D Douglas; S Lee; A Wiznia; S Pelton; R Yogev; K McIntosh; S Nachman
Journal:  J Infect Dis       Date:  2000-06-27       Impact factor: 5.226

9.  Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects.

Authors:  D V Havlir; R D Schrier; F J Torriani; K Chervenak; J Y Hwang; W H Boom
Journal:  J Infect Dis       Date:  2000-10-18       Impact factor: 5.226

10.  Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.

Authors:  A Mocroft; A N Phillips; J Gatell; B Ledergerber; M Fisher; N Clumeck; M Losso; A Lazzarin; G Fatkenheuer; J D Lundgren
Journal:  Lancet       Date:  2007-08-04       Impact factor: 79.321

View more
  13 in total

1.  T cell responses of HIV-infected children after administration of inactivated or live attenuated influenza vaccines.

Authors:  Adriana Weinberg; Lin-Ye Song; Terence Fenton; Sharon A Nachman; Jennifer S Read; Julie Patterson-Bartlett; Myron J Levin
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

2.  Quantification of CD4 responses to combined antiretroviral therapy over 5 years among HIV-infected children in Kinshasa, Democratic Republic of Congo.

Authors:  Andrew Edmonds; Marcel Yotebieng; Jean Lusiama; Yori Matumona; Faustin Kitetele; David Nku; Sonia Napravnik; Stephen R Cole; Annelies Van Rie; Frieda Behets
Journal:  J Acquir Immune Defic Syndr       Date:  2012-09-01       Impact factor: 3.731

3.  Opportunistic illnesses in Brazilian children with AIDS: results from two national cohort studies, 1983-2007.

Authors:  Alberto N Ramos; Luiza H Matida; Norman Hearst; Jorg Heukelbach
Journal:  AIDS Res Ther       Date:  2011-07-18       Impact factor: 2.250

4.  Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays.

Authors:  Adriana Weinberg; Lin Ye Song; Cindy L Wilkening; Terry Fenton; John Hural; Raul Louzao; Guido Ferrari; Paige E Etter; Mark Berrong; Jennifer D Canniff; Donald Carter; Olivier D Defawe; Ambrosia Garcia; Tania L Garrelts; Rebecca Gelman; Linda K Lambrecht; Savita Pahwa; Sudheesh Pilakka-Kanthikeel; David L Shugarts; Nancy B Tustin
Journal:  J Immunol Methods       Date:  2010-10-01       Impact factor: 2.303

5.  Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes.

Authors:  Russell B Van Dyke; Kunjal Patel; George K Siberry; Sandra K Burchett; Stephen A Spector; Miriam C Chernoff; Jennifer S Read; Lynne M Mofenson; George R Seage
Journal:  J Acquir Immune Defic Syndr       Date:  2011-06-01       Impact factor: 3.731

6.  Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation.

Authors:  Dwight E Yin; Meredith G Warshaw; William C Miller; Hannah Castro; Susan A Fiscus; Lynda M Harper; Linda J Harrison; Nigel J Klein; Joanna Lewis; Ann J Melvin; Gareth Tudor-Williams; Ross E McKinney
Journal:  Pediatrics       Date:  2014-10       Impact factor: 7.124

Review 7.  Immunology of pediatric HIV infection.

Authors:  Nicole H Tobin; Grace M Aldrovandi
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

8.  Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children.

Authors:  Myron J Levin; Jeffrey P Anderson; George R Seage; Paige L Williams
Journal:  J Acquir Immune Defic Syndr       Date:  2009-02-01       Impact factor: 3.731

9.  Changes in cellular immune activation and memory T-cell subsets in HIV-infected Zambian children receiving HAART.

Authors:  Kaitlin Rainwater-Lovett; Hope Nkamba; Mwangelwa Mubiana-Mbewe; Carolyn B Moore; Joseph Margolick; William J Moss
Journal:  J Acquir Immune Defic Syndr       Date:  2014-12-15       Impact factor: 3.731

10.  Rate of candidiasis among HIV-infected children in Spain in the era of highly active antiretroviral therapy (1997-2008).

Authors:  Alejandro Álvaro-Meca; Julia Jensen; Dariela Micheloud; Asunción Díaz; Dolores Gurbindo; Salvador Resino
Journal:  BMC Infect Dis       Date:  2013-03-04       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.